Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC-Reference-Cited by-同舟云学术

Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC

Published:2020-06-16 Issue:9 Volume:59 Page:1051-1057
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Halvorsen Tarje O.¹²,Stokke Kristin¹²,Killingberg Kristin T.¹²,Raj Sunil X.¹²,Sørhaug Sveinung³,Brustugun Odd Terje⁴,Fløtten Øystein⁵,Helbekkmo Nina⁶,Hornslien Kjersti⁷,Madebo Tesfaye⁸,Fluge Sverre⁹,Grønberg Bjørn Henning¹²

Affiliation:

1. Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway;

2. Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway;

3. Department of Thoracic Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway;

4. Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway;

5. Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway;

6. Department of Pulmonology, University Hospital of North Norway, Tromsø, Norway;

7. Department of Oncology, Oslo University Hospital, Oslo, Norway;

8. Department of Pulmonary Medicine, Stavanger University Hospital, Stavanger, Norway;

9. Department of Pulmonary Medicine, Haugesund Hospital, Haugesund, Norway

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1778179

Reference27 articles.

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

2. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer

3. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

5. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations between Measured and Patient-Reported Physical Function and Survival in Advanced NSCLC;Healthcare;2022-05-17

2. Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma;Asia-Pacific Journal of Clinical Oncology;2022-04-20

3. Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer;Clinical Medicine Insights: Oncology;2022-01

4. Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting;Journal of Thoracic Disease;2021-03